FDA rejects AMAG Pharma's single-dose hormone injection

AMAG Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration rejected a single dose use of its hormone injection, Makena, the agency's second rejection in six months.

Makena is currently approved and marketed in a multi-dose injection and remains unaffected by FDA's rejection of the single-dose vial.

More on this...

The multiple dose is approved to be used to lower premature birth in pregnant women who has had one premature baby.